Press Release

Illumina to Announce Second Quarter 2013 Financial Results on Tuesday, July 23, 2013

SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2013 following the close of market on Tuesday, July 23, 2013.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jay Flatley, President and Chief Executive Officer, Marc Stapley, Senior Vice President and Chief Financial Officer, and Christian Henry, Senior Vice President and General Manager, Genomic Solutions, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, July 23, 2013. Interested parties may listen to the call by dialing 888.680.0879 (passcode: 22024538), or if outside North America, by dialing +1.617.213.4856 (passcode: 22024538). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 4:00 pm Pacific Time (7:00 pm Eastern Time) on July 23, 2013 through July 30, 2013 by dialing 888.286.8010 (passcode: 66585327), or if outside North America, by dialing +1.617.801.6888 (passcode: 66585327).

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

Recent Articles

Studying epigenetics to avoid unwanted effects of blood transfusions
Studying epigenetics to avoid unwanted effects of blood transfusions
Illumina showcases innovations at the 7th China International Import Expo
Video: Illumina showcases innovations at the 7th China International Import Expo
Programs around the globe bring newborn screening into the Genome Era
Programs around the globe bring newborn screening into the Genome Era